THURSDAY, May 15, 2025 (HealthDay News) -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity ...

OBJECTIVE Gastric bypass (GB) surgery is associated with postprandial hyperinsulinemia, and this effect is accentuated in postsurgical patients who develop recurrent hypoglycemia. Plasma levels of ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Rates of metabolic and bariatric surgeries (MBS) rose by almost 15% in teenagers in the US between 2021 and 2023, despite falling in adults, new research has found. The cross-sectional analysis, ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

DALLAS — Results presented at the American Association of Hip and Knee Surgeons Annual Meeting showed 14 days may be the optimal cutoff time for glucagon-like peptide-1 receptor agonists prior ...

PRAC is recommending that patients who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs) consider the risk of delayed gastric emptying before undergoing surgery with general anesthesia or deep ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

The effect of glucagon-like peptide-1 receptor agonists on serum uric acid concentration: a systematic review and meta-analysis. Br J Clin Pharmacol 2022;88:3627-3637. Crossref ...

The researchers found that over a median of 7.5 years, ORC occurred in 5.62 cases per 1,000 person-years in the BMS group and in 5.89 cases per 1,000 person-years in the GLP-1 RA group (adjusted ...